English

SmartCella initiates Phase I/IIa clinical study with Extroducer® for targeted delivery of chemotherapy in pancreatic cancer

SmartCella and Oloker enter Extroducer® licensing agreement, advancing targeted delivery strategy

SmartCella publishes its 2025 Annual Report

SmartCella represents business sector in Swedish Government delegation to Boston

SmartCella and Catalent sign nonexclusive license agreement for GMP iPSCs

SmartCella appoints Professor Jan Lundberg to Scientific Advisory Board

First patient dosed in XyloCor Therapeutics’ Phase IIb trial using SmartCella’s Extroducer delivery platform

SmartCella forms Scientific Advisory Board with leading global scientific experts

Procella obtains regulatory approval to widen the scope of cell therapy manufacturing for clinical stages

SmartCella publishes its 2024 Annual Report